Baird served as co-manager on this offering
AboutBeiGene, Ltd. (“BeiGene” or the “Company”) (NASDAQ-GS: BGNE) recently completed a follow-on offering of 2,465,000 American Depositary Shares (“ADSs”), each representing 13 ordinary shares, at a price of $71.00 per ADS, generating gross proceeds of approximately $175.0 million. The Company intends to use proceeds from the offering for working capital and general corporate purposes, including research and development activities.
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. The Company is headquartered in Camana Bay, Grand Cayman.
CONTACT US TO LEARN MORE
- August 2017
- BeiGene, Ltd.
- Target Location